Astellas buys private oncology firm Ganymed €422mm, plus potential earnouts
Executive Summary
Astellas Pharma Inc. is paying €422mm ($460mm) in cash to acquire cancer-focused Ganymed Pharmaceuticals AG. Astellas will also shell out up to €860mm ($938mm) based on the progress in development of Ganymed's lead program IMAB362, which is currently in Phase IIb for gastroesophageal cancer.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Drug Discovery Tools
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice